Tuesday, October 27, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· July 20, 2026

American Fusion Inc. (OTC: AMFN) Receives Texas DSHS Certificate for All 12 Registered Texatron™ Fusion Engine™ Models; Testing Expected the Week of July 27, 2026

View original at globenewswire.com
American Fusion Inc. (OTC: AMFN) Receives Texas DSHS Certificate for All 12 Registered Texatron™ Fusion Engine™ Models; Testing Expected the Week of July 27, 2026 SOUTHLAKE, Texas, July 20, 2026 (GLOBE NEWSWIRE) -- American Fusion Inc…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The certificate does not certify commercial performance but provides authorization to conduct the covered research program; the next objective is generating credible, reproducible and properly documented technical data.

    60% confidence
  • The DSHS certificate covering all 12 registered Texatron™ models represents one of the most significant operational milestones in the Company's development and moves it closer to obtaining technical data required for future commercialization.

    60% confidence
  • This milestone represents another major step in American Fusion's development, bringing together scientific innovation, regulatory discipline, experienced personnel and a clear testing program.

    60% confidence
  • Excitement about beginning planned Texatron™ testing at Texas Tech, applying advanced scientific instrumentation and disciplined testing procedures to evaluate an innovative compact-fusion platform.

    60% confidence
  • Receiving the certificate for all 12 Texatron™ model classes is an extraordinary achievement enabling a new phase of disciplined experimental evaluation, including re-testing the 500-kilowatt system and beginning work on the 5-megawatt Texatron™.

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com